Fibrolamellar Carcinoma Clinical Trials

4 recruiting

Fibrolamellar Carcinoma Trials at a Glance

6 actively recruiting trials for fibrolamellar carcinoma are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Houston, Memphis, and Boston. Lead sponsors running fibrolamellar carcinoma studies include Allison O'Neill, MD, Children's Oncology Group, and Federation Francophone de Cancerologie Digestive.

Browse fibrolamellar carcinoma trials by phase

Treatments under study

About Fibrolamellar Carcinoma Clinical Trials

Looking for clinical trials for Fibrolamellar Carcinoma? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Fibrolamellar Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Fibrolamellar Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 2

Agnostic Therapy in Rare Solid Tumors

Cancer of Unknown PrimarySoft Tissue SarcomaCholangiocarcinoma+38 more
Instituto do Cancer do Estado de São Paulo28 enrolled8 locationsNCT06638931
Recruiting
Phase 1Phase 2

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular CarcinomaRefractory Solid TumorPediatric Solid Tumor+3 more
St. Jude Children's Research Hospital64 enrolled2 locationsNCT05468359
Recruiting
Phase 1Phase 2

Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

Stage III Hepatocellular Carcinoma AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8+4 more
M.D. Anderson Cancer Center15 enrolled1 locationNCT04380545
Recruiting
Phase 2

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

Liver CancerFibrolamellar CarcinomaHepatocellular Carcinoma, Childhood+1 more
Allison O'Neill, MD18 enrolled5 locationsNCT04134559
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Childhood Malignant Solid Neoplasm+6 more
Children's Oncology Group81 enrolled20 locationsNCT06620302
Recruiting

A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers

CholangiocarcinomaHepatoblastomaFibrolamellar Carcinoma+7 more
Federation Francophone de Cancerologie Digestive150 enrolled40 locationsNCT06541652